Lipoprotein-associated phospholipase A₂: a novel marker of cardiovascular risk and potential therapeutic target

Bibliography

• GRUNDY SM, CLEEMAN JI, BAIREY MERZ CN et al: Implications of recent clinical trials for the National Cholesterol Education Programme Adult Treatment Panel III Guidelines. J. Am. Coll. Cardiol (2004) 44:720–732.
   PubMed Web of Science ®Google Scholar
• GREENLAND P, KNOLL MD, STAMLER J et al: Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. IA/VIA (2003) 290:891–897.
   Web of Science ®Google Scholar
• DOWNS JR, CLEARFIELD M, WETS S et al.: For the Air Force/Texas Coronary Atherosclerosis Prevention Study. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/ TexCAPS. JAMA (1998) 279:1615–1622.
   Google Scholar
• SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY GROUP: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 344:1383–1389.
   PubMed Web of Science ®Google Scholar
• SACKS FM, PFEFFER MA, MOYE LA et al.: For the Cholesterol and Recurrent Events Trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl. J. Med. (1996) 335:1001–1009.
   Google Scholar
• LONG-TERM INTERVENTION WITH PRAVASTATIN IN ISCHEMIC DISEASE (LIPID) STUDY GROUP: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl. J. Med. (1998) 339:1349–1357.
   PubMed Web of Science ®Google Scholar
• SHEPHERD J, COBBE SM, FORD I et al: For the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl. J. Med. (1995) 333:1301–1307.
   Google Scholar
• SEVER PS, DAHLOF B, POULTER NR et al: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multi-centre randomized controlled trial. Lancet (2003) 361:1149–1158.
   PubMed Web of Science ®Google Scholar
• SHEPHERD J, BLAUW GJ, MURPHY MB et al.: Prospective Study of Pravastatin in the Elderly at Risk study group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet (2002) 360:1623–1630.
   Google Scholar
• HEART PROTECTION STUDY COLLABORATIVE GROUP: MRC/ MHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet (2002) 360:7–22.
   PubMed Web of Science ®Google Scholar
• CANNON CP, BRAUNWALD E, McCABE CH et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl. J. Med. (2004) 350:1495–1504.
   PubMed Web of Science ®Google Scholar
• ROSS R: Atherosclerosis-an inflammatory disease. N Engl. I Med. (1999) 340:115–126.
   PubMed Web of Science ®Google Scholar
• ••An excellent overview of the inflammatoryprocesses involved in atherogenesis.
   Google Scholar
• LIBBY P, RIDKER PM, MASERI A: Inflammation and atherosclerosis. Circulation (2002) 105:1135–1143.
   PubMed Web of Science ®Google Scholar
• ••A concise review of inflammation inatherosclerosis.
   Google Scholar
• SIX DA, DENNIS EA: The expanding superfamily of phospholipase A(2) enzymes: classification and characterization. Biochim. Biophys. Acta (2000) 1488:1–19.
   PubMed Web of Science ®Google Scholar
• TJOELKER LW, WILDER C, EBERHARDT C et al: Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature (1995) 374:549–553.
   PubMed Web of Science ®Google Scholar
• STAFFORINI DM, PRESCOTT SM, McINTYRE TM: Human plasma platelet-activating factor acetylhydrolase. Purification and properties. j. Biol. Chem. (1987) 262:4223–4230.
   PubMed Web of Science ®Google Scholar
• STAFFORINI DM, McINTYRE TM, ZIMMERMAN GA, PRESCOTT SM: Platelet-activating factor acetylhydrolases. Biol. Chem. (1997) 272:17895–17898.
   Web of Science ®Google Scholar
• WATSON AD, NAVAB M, HAMA SY et al.: Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J. Clin. Invest. (1995) 95:774–782.
   PubMed Web of Science ®Google Scholar
• HENIG NR, AITKEN ML, LIU MC, YU AS, HENDERSON WR Jr: Effect of recombinant human platelet-activating factor-acetylhydrolase on allergen-induced 676 Expert Op/n. Investig. Drugs (2005) 14(6) asthmatic responses. Am. I Respir Grit. Care Med. (2000) 162:523–527.
   Google Scholar
• OPAL S, LATERRE PF, ABRAHAM E et al.: Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a Phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial. Crit. Care Med. (2004) 32:332–341.
   PubMed Web of Science ®Google Scholar
• STEINBERG D: Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat. Med. (2002) 8:1211–1217.
   PubMed Web of Science ®Google Scholar
• STAFFORINI DM, ELSTAD MR, McINTYRE TM, ZIMMERMAN GA, PRESCOTT SM: Human macrophages secrete platelet-activating factor acetylhydrolase. J. Biol. Chem. (1990) 265:9682–9687.
   PubMed Web of Science ®Google Scholar
• •One of the first studies demonstrating that Lp-PLA2 is secreted by the cell types Involved in atherogenesis.
   Google Scholar
• ASANO K, OKAMOTO S, FUKUNAGA K et al: Cellular source (s) of platelet-activating-factor acetylhydrolase activity in plasma. Biochem. Biophys. Res. Commun. (1999) 261:511–514.
   PubMed Web of Science ®Google Scholar
• STAFFORINI DM, TJOELKER LW, McCORMICK SP et al: Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein. J. Biol. Chem. (1999) 274:7018–7024.
   PubMed Web of Science ®Google Scholar
• MACPHEE CH, MOORES KE, BOYD HF et al: Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem. J. (1999) 338\(Part 2):479–487.
   Google Scholar
• ••The atherogenic role of Lp-PLA2 isexplored along with the biological effects of lysoPC and oxNEFA.
   Google Scholar
• MARATHE GK, HARRISON KA, MURPHY RC, PRESCOTT SM, ZIMMERMAN GA, McINTYRE TM: Bioactive phospholipid oxidation products. Free Radic. Biol. Med. (2000) 28:1762–1770.
   PubMed Web of Science ®Google Scholar
• KABAROWSKI JH, ZHU K, LE LQ, WITTE ON, XU Y: Lysophosphatidylcholine as a ligand for the immunoregulatory receptor G2A. Science (2001) 293:702–705.
   PubMed Web of Science ®Google Scholar
• RIKITAKE Y, HIRATA K, YAMASHITA T et al.: Expression of G2A, a receptor for lysophosphatidylcholine, by macrophages in murine, rabbit, and human atherosclerotic plaques. Arterioscler. Thromb. Vasc. Biol. (2002) 22:2049–2053.
   PubMed Web of Science ®Google Scholar
• CHAI YC, HOWE PH, DI CORLETO PE, CHISOLM GM: Oxidized low density lipoprotein and lysophosphatidylcholine stimulate cell cycle entry in vascular smooth muscle cells. Evidence for release of fibroblast growth factor-2. J. Biol Chem. (1996) 271:17791–17797.
   Google Scholar
• CHANG MY, TSOI C, WIGHT TN, CHAIT A: Lysophosphatidylcholine regulates synthesis of biglycan and the proteoglycan form of macrophage colony stimulating factor. Arterioscler. Thromb. Vasc. Biol. (2003) 23:809–815.
   PubMed Web of Science ®Google Scholar
• LIU-WU Y, HURT-CAMEJO E, WIKLUND 0: Lysophosphatidylcholine induces the production of IL-10 by human monocytes. Atherosclerosis (1998) 137:351–357.
   PubMed Web of Science ®Google Scholar
• OESTVANG J, ANTHONSEN MW, JOHANSEN B: Role of secretory and cytosolic phospholipase A(2) enzymes in lysophosphatidylcholine-stimulated monocyte arachidonic acid release. FEBS Lett. (2003) 555:257–262.
   PubMed Web of Science ®Google Scholar
• CARPENTER KL, DENNIS IF, CHALLIS IR et al: Inhibition of lipoprotein-associated phospholipase A2 diminishes the death-inducing effects of oxidised LDL on human monocyte-macrophages. FEBS Lett. (2001) 505:357–363.
   PubMed Web of Science ®Google Scholar
• •The findings from this study provide evidence that lysoPC has pro-atherogenic effects and that blocking Lp-PLA2 activity reduces lysoPC levels and subsequent cytotoxicity.
   Google Scholar
• KUME N, CYBULSKY MI, GIMBRONE MA Jr: Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J. Clin. Invest. (1992) 90:1138–1144.
   PubMed Web of Science ®Google Scholar
• ZHU Y, LIN JH, LIAO HL, VERNA L,STEMERMAN MB: Activation of ICAM-1 promoter by lysophosphatidylcholine: possible involvement of protein tyrosine kinases. Biochim. Biophys. Acta. (1997) 1345:93–98.
   PubMed Web of Science ®Google Scholar
• TAKAHARA N, KASHIWAGI A, MAEGAWA H, SHIGETA Y: Lysophosphatidylcholine stimulates the expression and production of MCP-1 by human vascular endothelial cells.Metabolism (1996) 45:559–564.
   PubMed Web of Science ®Google Scholar
• WONG JT, TRAN K, PIERCE GN, CHAN AC, 0 K, CHOY PC: Lysophosphatidylcholine stimulates the release of arachidonic acid in human endothelial cells. Biol. Chem. (1998) 273:6830–6836.
   Web of Science ®Google Scholar
• RIKITAKE Y, KAWASHIMA S, YAMASHITA T et al.: Lysophosphatidylcholine inhibits endothelial cell migration and proliferation via inhibition of the extracellular signal-regulated kinase pathway. Arterioscler. Thromb. Vasc. Biol. (2000) 20:1006–1012.
   PubMed Web of Science ®Google Scholar
• FUKAO M, HATTORI Y, KANNO M, SAKUMA I, KITABATAKE A: Structural differences in the ability of lysophospholipids to inhibit endothelium-dependent hyperpolarization by acetylcholine in rat mesenteric arteries. Biochem. Biophys. Res. Commun. (1996) 227:479–483.
   PubMed Web of Science ®Google Scholar
• CHEN L, LIANG B, FROESE DE et al:Oxidative modification of low density lipoprotein in normal and hyperlipidemic patients: effect of lysophosphatidylcholine composition on vascular relaxation. Lipid Res. (1997) 38:546–553.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI M, OKAZAKI H, OGATAY, TAKEUCHI K, IKEDA U, SHIMADA K: Lysophosphatidylcholine induces apoptosis in human endothelial cells through a p38-mitogen-activated protein kinase-dependent mechanism. Atherosclerosis (2002) 161:387–394.
   PubMed Web of Science ®Google Scholar
• RONG JX, BERMAN JW, TAUBMAN MB, FISHER EA: Lysophosphatidylcholine stimulates monocyte chemoattractant protein-1 gene expression in rat aortic smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. (2002) 22:1617–1623.
   PubMed Web of Science ®Google Scholar
• YAMAKAWA T, TANAKA S, YAMAKAWA Y et al.: Lysophosphatidylcholine activates extracellular signal-regulated kinases 1/2 through reactive oxygen species in rat vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. (2002) 22:752–758.
   PubMed Web of Science ®Google Scholar
• KOHNO M, YOKOKAWA K, YASUNARI K et al: Induction by lysophosphatidylcholine, a major phospholipid component of atherogenic lipoproteins, of human coronary artery smooth muscle cell migration. Circulation (1998) 98:353–359.
   PubMed Web of Science ®Google Scholar
• HSIEH CC, YEN MH, LIU HW, LAU YT: Lysophosphatidylcholine induces apoptotic and non-apoptotic death in vascular smooth muscle cells: in comparison with oxidized LDL. Atherosclerosis (2000) 151:481–491.
   PubMed Web of Science ®Google Scholar
• McMURRAY HF, PARTHASARATHY S, STEINBERG D: Oxidatively modified low density lipoprotein is a chemoattractant for human T lymphocytes. J. Clin. Invest. (1993) 92:1004–1008.
   PubMed Web of Science ®Google Scholar
• MACPHEE CH: Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic target. Curr. Opin. Pharmacol. (2001) 1:121–125.
   PubMedGoogle Scholar
• THEILMEIER G, DE GEEST B, VAN VELDHOVEN PP et al.: HDL-associated PAF-AH reduces endothelial adhesiveness in apoE / mice. FASEB J. (2000) 14:2032–2039.
   Google Scholar
• QUARCK R, DE GEEST B, STENGEL D et al.: Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice. Circulation (2001) 103:2495–2500.
   PubMed Web of Science ®Google Scholar
• MERTENS A, VERHAMME P, BIELICKI JK et al.: Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice. Circulation (2003) 107:1640–1646.
   PubMed Web of Science ®Google Scholar
• SINGH U, ZHONG S, XIONG M, LIT, SNIDERMAN A, TENG BB: Increased plasma non-esterified fatty acids and platelet-activating factor acetylhydrolase are associated with susceptibility to atherosclerosis in mice. Clin. Sci. (2004) 106:421–432.
   PubMed Web of Science ®Google Scholar
• PACKARD CJ, O'REILLY DS, CASLAKE MJ eta]: Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl. I Med. (2000) 343:1148–1155.
   PubMed Web of Science ®Google Scholar
• •A potential landmark study suggesting that Lp-PLA2 is a strong predictor of events, independent of traditional risk factors, LDL or C-reactive protein.
   Google Scholar
• BLAKE GJ, DADA N, FOX JC, MANSON JE, RIDKER PM: A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. J. Am. Coll Cardiol. (2001) 38:1302–1306.
   PubMed Web of Science ®Google Scholar
• BALLANTYNE CM, HOOGEVEEN RC, BANG H et al.: Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation (2004) 109:837–842.
   PubMed Web of Science ®Google Scholar
• KOENIG W, KHUSEYINOVA N, LOWEL H, TRISCHLER G, MEISINGER C: Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation (2004) 110: 1903-1908.
   Google Scholar
• BRILAKIS ES, McCONELL JP, LENNON RJ, ELSBER AA, MEYER JG, BERGER PB: Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur. Heart' (2005) 26:137–144.
   PubMed Web of Science ®Google Scholar
• OEI HHS, VAN DER MEER IM, HOFMAN A et al: Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke. Circulation (2005) 111:570–575.
   PubMed Web of Science ®Google Scholar
• MANOLIO T: Novel risk markers and clinical practice. N Engl. J. Med. (2003) 349:1587–1589.
   PubMed Web of Science ®Google Scholar
• DADA N, KIM NW WOLFERT RL: Lp-PLA2: an emerging biomarker of coronary heart disease. Expert Rev Mol. Diagn. (2002) 2:17–22.
   PubMedGoogle Scholar
• IRIBARREN C, GROSS MD, DARBINIAN JA, JACOBS DR Jr, SIDNEY S, LORIA CM: Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: the CARDIA study. Arterioscler. Thromb. Vasc. Biol. (2005) 25:216–221.
   PubMed Web of Science ®Google Scholar
• ISHIHARA M, IWASAKI T, NAGANO M et al: Functional impairment of two novel mutations detected in lipoprotein-associated phospholipase A2 (Lp-PLA2) deficiency patients. J. Hum. Genet. (2004) 49:302–307.
   PubMed Web of Science ®Google Scholar
• STAFFORINI DM, SATOH K, ATKINSON DL et al.: Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase. j Clin. Invest. (1996) 97:2784–2791.
   Google Scholar
• HIRAMOTO M, YOSHIDA H, IMAIZUMI T, YOSHIMIZU N, SATOH K: A mutation in plasma platelet-activating factor acetylhydrolase (Va1279-Phe) is a genetic risk factor for stroke. Stroke (1997) 28:2417–2420.
   PubMed Web of Science ®Google Scholar
• YAMADA Y, ICHIHARA S, FUJIMURA T, YOKOTA M: Identification of the G994 T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men. Metabolism (1998) 47:177–181.
   PubMed Web of Science ®Google Scholar
• UNNO N, NAKAMURA T, KANEKO H et al.: Plasma platelet-activating factor acetylhydrolase deficiency is associated with atherosclerotic occlusive disease in Japan. Vasc. Surg. (2000) 32:263–267.
   Google Scholar
• UNNO N, NAKAMURA T, MITSUOKA H et al: Association of a G994 T missense mutation in the plasma platelet-activating factor acetylhydrolase gene with risk of abdominal aortic aneurysm in Japanese. Ann. Surg. (2002) 235:297–302.
   PubMed Web of Science ®Google Scholar
• YAMADA Y, IZAWA H, ICHIHARA S et al.: Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl. J. Med. (2002) 347:1916–1923.
   PubMed Web of Science ®Google Scholar
• KIM PS, ARVAN P: Endocrinopathies inthe family of endoplasmic reticulum (ER) storage diseases: disorders of protein trafficking and the role of ER molecular chaperones. Endocr. Rev. (1998) 19:173–202.
   PubMed Web of Science ®Google Scholar
• ZHANG K, KAUFMAN RJ: Signaling theunfolded protein response from the endoplasmic reticulum. ./. Biol. Chem. (2004) 279:25935–25938.
   PubMed Web of Science ®Google Scholar
• KRUSE S, MAO XQ, HEINZMANN A et al: The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma. Am. Hum. Genet. (2000) 66:1522–1530.
   PubMed Web of Science ®Google Scholar
• ABUZEID AM, HAWE E, HUMPHRIES SE, TALMUD PJ: Association between the Ala379Val variant of the lipoprotein associated phospholipase A2 and risk of myocardial infarction in the north and south of Europe. Atherosclerosis (2003) 168:283-288. 678 Expert Op/n. lnvestig. Drugs (2005) 14(6)
   Google Scholar
• WHEELER JG, KEAVNEY BD, WATKINS H, COLLINS R, DANESH J: Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet (2004) 363:689–695.
   PubMed Web of Science ®Google Scholar
• KRAUSS RIVI: Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr. Opin. Lipidol (1994) 5:339–349.
   PubMedGoogle Scholar
• TSELEPSIS AD, DENTAN C, KARABINA SA, CHAPMAN MJ, NINIO E: PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme. Arterioscler. Thromb. Vase. Biol. (1995) 15:1764–1773.
   PubMed Web of Science ®Google Scholar
• DE CASTELLARNAU C, SANCHEZ-QUESADA JL, BENITEZ S et al: Electronegative LDL from normolipemic subjects induces IL-8 and monocyte chemotactic protein secretion by human endothelial cells. Arterioscler. Thromb. Vase. Biol. (2000) 20:2281–2287.
   PubMed Web of Science ®Google Scholar
• HODIS HN, KRAMSCH DM, AVOGARO P et al: Biochemical and cytotoxic characteristics of an in vivo circulating oxidized low density lipoprotein (LDL-). J. Lipid Res. (1994) 35:669–677.
   PubMed Web of Science ®Google Scholar
• DEMUTH K, MYARA I, CHAPPEY B et al.: A cytotoxic electronegative LDL subfraction is present in human plasma. Arterioscler. Thromb. Vase. Biol. (1996) 16:773–783.
   PubMed Web of Science ®Google Scholar
• YANG CY, RAYA JL, CHEN HH et al:Isolation, characterization, and functional assessment of oxidatively modified subfractions of circulating low-density lipoproteins. Arterioscler. Thromb. Vase. (2003) 23:1083–1090.
   PubMed Web of Science ®Google Scholar
• BENITEZ S, SANCHEZ-QUESADA JL, RIBAS V et al.: Platelet-activating factor acetylhydrolase is mainly associated with electronegative low-density lipoprotein subfraction. Circulation (2003) 108:92–96.
   PubMed Web of Science ®Google Scholar
• HAKKINEN T, LUOMA JS, HILTUNEN MO: Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler. Thromb. Vase. Biol. (1999) 19:2909–2917.
   PubMed Web of Science ®Google Scholar
• •The findings from this study suggest that the expression of Lp-PLA2 is upregulated in human atheroma.
   Google Scholar
• KOLODGIE F, BURKE A, TAYE A, LIU W, SUDHIR K, VIRMANI R: Lipoprotein-associated phospholipase A2 is highly expressed in macrophages of coronary lesions prone to rupture. Circulation (2004) 110:111–246.
   Google Scholar
• JOHNSON A, ZALEWSKI A, JANMOHAMED S et al: Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity, an emerging CV risk marker, can be inhibited in atherosclerotic lesions and plasma by novel pharmacologic intervention: The results of a multicenter clinical study. Circulation (2004) 110:111–590.
   Google Scholar
• RIDKER PM, CANNON CP, MORROW D et al.: C-reactive protein levels and outcomes after statin therapy. N Engl. J. Med. (2005) 352:20–28.
   PubMed Web of Science ®Google Scholar
• RIDKER PM, RIFAI N, PFEFFER MA et al.: Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation. (1998) 98:839–844.
   Google Scholar
• TSIMIHODIMOS V, KARABINA SA, TAMBAKI AP et al: Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of Type IIA and Type IIB. Arterioscler. Thromb. Vase. Biol. (2002) 22:306–311.
   PubMed Web of Science ®Google Scholar
• TSIMIHODIMOS V, KAKAFIKA A, TAMBAKI AP, BAIRAKTARI E et al: Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins. J. Lipid Res. (2003) 44:927–934.
   PubMed Web of Science ®Google Scholar
• TAMBAKI AP, RIZOS E, TSIMIHODIMOS V, TSELEPSIS AD, ELISAF M: Effects of antihypertensive and hypolipidemic drugs on plasma and high-density lipoprotein-associated platelet activating factor-acetylhydrolase activity. Cardiovasc. Phannacol. Ther. (2004) 9:91–95.
   PubMed Web of Science ®Google Scholar